VERAXA Biotech AG (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has announced the appointment of Raju Willener as chief financial officer, effective immediately. Willener brings more than three decades of international financial leadership experience spanning global capital markets, investment banking, corporate finance, asset management, and strategic leadership. He will report to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to support the company’s capital strategy, strategic opportunities, and continued development of its proprietary BiTAC(R) technology platform and oncology pipeline.
The appointment comes at a critical time for VERAXA as it advances its pipeline of bispecific T cell engagers, bispecific antibody-drug conjugates (ADCs), and other innovative formats into clinical development. Willener’s extensive background in corporate finance and capital markets is poised to strengthen the company’s financial foundation and facilitate its growth trajectory. Prior to joining VERAXA, Willener served as director of corporate development at Exentis Group AG before being appointed CFO in 2025, where he led M&A initiatives, financial strategy, and key corporate functions. Earlier in his career, he held senior executive and investment positions overseeing areas including corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management.
Willener’s appointment is a strategic move for VERAXA as it seeks to leverage its innovative BiTAC(R) technology, which was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL). The company’s focus on quality-by-design principles and its suite of transformative technologies position it well in the competitive oncology landscape. With Willener’s expertise, VERAXA is likely to enhance its ability to secure funding, forge strategic partnerships, and navigate the complexities of bringing novel therapies to market.
The implications of this leadership change are significant for investors and the biotech sector. A CFO with deep capital markets experience can be instrumental in optimizing financial strategies, managing investor relations, and identifying growth opportunities. For VERAXA, this appointment signals a commitment to robust financial management as it progresses toward clinical milestones. The company’s pipeline, including its proprietary BiTAC formats, holds promise for addressing unmet medical needs in oncology, and effective financial stewardship will be key to advancing these assets.
In the broader context, biotech companies often face challenges in funding lengthy and costly clinical trials. Having a CFO with a track record of managing large investment portfolios and leading M&A can provide the strategic insight needed to navigate these hurdles. VERAXA’s decision to bring Willener on board reflects a proactive approach to ensuring financial resilience and operational excellence.
As VERAXA continues to develop its next-generation antibody-based therapeutics, the appointment of Willener is expected to bolster investor confidence and support the company’s long-term vision. The company remains dedicated to advancing its oncology pipeline, and with Willener’s leadership, it is well-positioned to capitalize on emerging opportunities in the biopharmaceutical industry.
